Mind Medicine (mindmed) . Subordinate Voting Shares Stock News

MindMed''s LSD trials are facing a regulatory roadblock but MNMD stock isn''t being forced down. Here''s why investors should watch.

Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) hit a new 52-week low on Tuesday . The company traded as low as 1.44 and last traded at 1.47, with a volume of 7451 shares. The stock had previously closed at 1.63. Separately, Zacks Investment Research lowered Mind Medicine (MindMed) from a hold rating to a sell []

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) has seen 2.78 million shares traded in the last trading session. The company, currently valued at $368.90M, closed the last trade at $1.63 per share which meant it lost -$0.09 on the day or -5.23% during that session. The MNMD stock price is -253.99% off its 52-week high price of … Mind Medicine (MindMed) Inc. (MNMD) Slumps -5.23%, A Loss For Bears Read More »

MindMed's LSD trials are facing a regulatory roadblock but MNMD stock isn't being forced down. Here's why investors should watch.

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylam

Agrify Taps Barry Turkanis To Its Board Of Directors Vertically integrated cannabis company Agrify Corporation (NASDAQ: AGFY) announced Tuesday that it has appointed Barry Turkanis to serve as an inde

The trading price of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) floating lower at last check on Tuesday, December 14, closing at $1.67, -3.74% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

PALM BEACH, Fla. , Dec. 14, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy - the medically approved use of MDMA, psilocybin, and LSD as a component of elevated psychotherapy programs. A study conducted by Yale on mice determined that one dose of psilocybin immediately increased neural connections in the brains. Doctors believe this helps the brain "reorganize and adapt" to different situations, improving response time. MDMA has recently been designated a breakthrough treatment for post-traumatic stress disorder (PTSD) by the U.S. Food and Drug Administration (FDA), opening the way for its approval within two years. In a study published in Nature Medicine, symptoms of depression were significantly reduced after three doses of MDMA given at monthly intervals.

(RTTNews) - Mind Medicine (MindMed) Inc.(MNMD), a company focused on psychedelic-inspired therapies, said on Tuesday that Robert Barrow has been named as its new chief executive officer or CEO. Barrow was serving as as interim CEO of MindMed after J.R. Rahn, resigned as the company''s Co-Founder and CEO, earlier this year. Effective…

-Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed -Carol Vallone appointed as Chair of the Board of Directors, Andreas Krebs appointed as Vice Chair and Perry Dellelce transitions from his role as Chairman- NEW YORK, Dec. 14, 2021…

Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ) announced Tuesday that Robert Barrow has been appointed CEO and member of the board of directors. Barrow, an

The stock price of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) increased by over 2% pre-market today. This is why it happened.

This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn. In learning more about the changes

This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD ), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn . In learning more about the changes that have taken place since, Benzinga spoke with Robert Barrow , the firms chief development officer, who took the role of CEO after Rahn. Context: In light of the stagnation of traditional mental health care infrastructure, MindMed launched to discover, develop and deploy treatments that address and avoid the adverse effects of abuse and dependence. During his tenure, Rahn introduced a broader audience to ongoing research and resource gaps around medicinal psychedelics. He raised $200 million, honed relationships with leading research groups and listed MindMed on Nasdaq Inc (NASDAQ: NDAQ ), bolstering innovation and allowing both retail and institutional investors a chance to participate in the new age of medicine. However, Rahn felt it was time to step away. He told Benzinga that MindMed was a brand that needed to focus more on drug development. Every company needs a different leader for a different time, he had said. I believe I was the right leader, at the right time and this transition is just a natural progression. About Barrow: My background is in the pharmaceutical industry where I was, for about 10 years, the chief operating officer of a clinical-stage drug development company, Barrow said of